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Abstract
Purpose Omacetaxine mepesuccinate is a first-in-class
cephalotaxine demonstrating clinical activity in chronic
myeloid leukemia. A subcutaneous (SC) formulation
demonstrated efficacy and safety in phase 1/2 trials in
patients previously treated with C1 tyrosine kinase inhib-
itor. This study assessed pharmacokinetics and safety of SC
omacetaxine in patients with advanced cancers.
Methods Omacetaxine 1.25 mg/m2 SC was administered
BID, days 1–14 every 28 days for 2 cycles, until disease
progression or unacceptable toxicity. Blood and urine were
collected to measure omacetaxine concentrations and
inactive metabolites. Adverse events, including QT interval
prolongation, were recorded. Tumor response was assessed
at cycle 2 completion.
Results Pharmacokinetic parameters were estimated from
cycle 1, day 1 data in 21 patients with solid tumors or
hematologic malignancies and cycle 1, day 11 data in 10
patients. Omacetaxine was rapidly absorbed, with mean peak
plasma concentrations observed within 1 h, and widely dis-
tributed, as evidenced by an apparent volume of distribution
of 126.8 L/m2. Plasma concentration versus time data dem-
onstrated biexponential decay; mean steady-state terminal
half-life was 7 h. Concentrations of inactive metabolites 40-
DMHHT and cephalotaxine were approximately 10 % of
omacetaxine and undetectable in most patients, respectively.
Urinary excretion of unchanged omacetaxine accounted for
\15 % of the dose. Grade 3/4 drug-related adverse events
included thrombocytopenia (48 %) and neutropenia (33 %).
Two grade 2 increases in QTc interval ([470 ms) were
observed and were not correlated with omacetaxine plasma
concentration. No objective responses were observed.
Conclusions Omacetaxine is well absorbed after SC
administration. Therapeutic plasma concentrations were
achieved with 1.25 mg/m2 BID, supporting clinical
development of this dose and schedule.
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Introduction
Omacetaxine mepesuccinate is a first-in-class cephalotax-
ine in clinical development as an antileukemic therapy.
Over 40 years ago, alcoholic extracts obtained from the
bark of the evergreen plum yew Cephalotaxus fortunei
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were found to contain alkaloids with significant antitumor
activity [1]. A semi-synthetic process was subsequently
developed that utilized the leaves of the tree, rather than the
bark, thereby allowing production of large quantities of
highly purified omacetaxine, which is chemically identical
to the natural product homoharringtonine [2].
Early phase 1 trials of omacetaxine in the United States
in patients with a variety of solid and hematologic malig-
nancies utilized short (over 60–90 min) intravenous (IV)
infusions, and dose-limiting, life-threatening hypotension
and tachycardia were observed at dose levels above
3–4 mg/m2 [3, 4]. Since then, further refinement of the
omacetaxine dose and schedule via a low-dose, continuous
IV infusion, or subcutaneous (SC) injection has been
demonstrated to largely ameliorate these cardiovascular
adverse effects [5–7].
Omacetaxine acts by binding to the A-site cleft of
ribosomes and transiently inhibiting protein synthesis [8].
In vitro, omacetaxine induces apoptosis in leukemic cells
due to a selective decrease in short-lived proteins, includ-
ing the antiapoptotic proteins Mcl-1 and cMyc [9, 10]. In
the mid-1990s, a phase 2 trial of omacetaxine in patients
with chronic myeloid leukemia (CML) produced a com-
plete hematologic response in[70 % of patients and major
cytogenetic response in approximately 15 % [5]. These
promising results were overshadowed by the introduction
of imatinib, the first tyrosine kinase inhibitor (TKI) tar-
geting the BCR-ABL oncogene in CML cells, and its
approval in 2001 [11]. Although TKI therapy is now the
standard of care for initial treatment of CML, interest in
omacetaxine has been renewed in recent years with the
recognition that resistance to initial TKI therapy occurs in
approximately 25 % of patients [12–14] and that only
62 % of patients remain in complete cytogenetic remission
at 6 years due to either acquired resistance or nonadher-
ence [15]. Moreover, TKIs are not active against CML
stem cells, promoting interest in other agents such as
omacetaxine that may target leukemic stem cells [16].
The safety and efficacy of SC omacetaxine in patients
with CML were evaluated in a phase 1/2, dose-escalation
study [6]. In this study, SC omacetaxine was well tolerated
up to a dose of 1.25 mg/m2 every 12 h [twice daily (BID)]
for 14 days [5]. Subsequently, SC omacetaxine (at the
same dose and schedule) demonstrated clinical activity and
tolerability in two phase 2, open-label, multicenter studies
in CML patients: one in patients with the T315I mutation
who had failed prior imatinib [17] and the second in CML
patients with resistance or intolerance to 2 TKIs [18].
Based on results of an analysis of these 2 studies [19], an
application for United States Food and Drug Administra-
tion (FDA) approval of SC omacetaxine at this dose and
schedule for patients with CML who failed previous
treatment with 2 TKIs has been submitted.
In support of the clinical development of SC omace-
taxine, the current study assessed the single- and multiple-
dose pharmacokinetics and safety of SC omacetaxine me-
pesuccinate at a dose of 1.25 mg/m2 BID for 14 days every
28 days in patients with relapsed and/or refractory hema-
tologic malignancies or advanced solid tumors.
Methods
Study design
This open-label, multicenter study was conducted in
accordance with current FDA regulations, International
Conference on Harmonisation Good Clinical Practice
guidelines, the principles of the Declaration of Helsinki,
and other applicable regulations and guidelines. Full ethi-
cal approval was granted by the institutional review boards
at participating institutions. The study was registered at
www.clinicaltrials.gov as NCT00675350.
Patients
Adult patients with a diagnosis of relapsed or refractory
CML, acute promyelocytic leukemia, acute myeloid leu-
kemia (AML), or myelodysplastic syndrome (MDS), or
those with advanced solid tumors who had exhausted or
become intolerant to all available therapies, were eligible
for participation. Additional inclusion criteria were life
expectancy of [12 weeks, an Eastern Cooperative Oncol-
ogy Group (ECOG) performance status B2, corrected QT
interval \450 ms, and adequate organ function. Excluded
were patients with previous omacetaxine treatment, NYHA
Class III/IV heart disease, any uncontrolled cardiac con-
dition, myocardial infarction within previous 12 weeks,
solid tumors with known bone marrow or central nervous
system involvement, active and uncontrolled systemic
infection, chemotherapy within 4 weeks prior to study or
radiation therapy within 6 weeks prior to study, or any
medical or psychiatric condition rendering the patient
unable to comply with study requirements. Written
informed consent was obtained from all participants.
Study drug administration
Omacetaxine 1.25 mg/m2 was administered SC every 12 h
on days 1–14 of each 28-day cycle. The first dose was
administered in the clinic by qualified site personnel who
trained patients and/or caregivers in the proper technique
for SC administration. Thereafter, the drug was given at
home by the patient or caregiver who recorded each
administration in a study diary; diaries were collected, and
patient compliance was reviewed each week. The planned
36 Cancer Chemother Pharmacol (2013) 71:35–41
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treatment duration was 2 cycles; if a response was docu-
mented after the first 2 cycles of treatment, patients were
eligible for continued treatment.
The dosing schedule could be modified for adverse
events (AEs). In patients who developed grade 4 neutro-
penia or grade C3 thrombocytopenia, treatment was
delayed until recovery to grade B2, and the number of
consecutive days of treatment was reduced by 2 days in
subsequent cycles. For nonhematologic toxicity, treatment
was delayed for grade C2 toxicity that was unresponsive to
supportive care and considered possibly related to study
drug. Upon resolution to baseline or grade B1, treatment
was resumed at the same dose and schedule (for grade 2
events) or with a reduction in the number of consecutive
dosing days for the remainder of that cycle only (for grade
C3 events).
Pharmacokinetic studies
Blood samples were collected from all patients on day 1
(predose and 0.5, 1, 2, 4, 8, and 12 h postdose); day 8
(predose); day 11 (predose and 0.5, 1, 2, 4, and 8 h after the
21st dose); day 15 (12–24 h after the 28th dose); and day
29 (predose). During study visits that included pharmaco-
kinetic sampling, patients administered study drug under
staff supervision. Urine for pharmacokinetic analysis was
collected on days 1 and 11 (predose and 0–6, 6–12, and
12–24 h postdose).
Plasma and urine concentrations of omacetaxine and its 2
inactive metabolites, 40-desmethylhomoharringtonine (40-
DMHHT) and cephalotaxine [20], were measured using a
liquid chromatography–tandem mass spectrometry method
developed, validated, and performed by Advion BioServic-
es, Inc. (Ithaca, NY). Blood samples were collected in tubes
containing dipotassium ethylenediamine tetraacetic acid and
treated with 0.02 % paraoxon. For plasma analyses, 100 lL
of plasma was processed by protein precipitation and ana-
lyzed using an XDB-Phenyl (2.1 9 50 mm, 5 lm) column
at ambient temperature with the Sciex API 5000, Analyst
Version 1.4.1, turbo ion spray, positive ionization, selected
reaction monitoring detection system. Deuterated analogs of
the compounds were used as internal standards. The lower
limits of quantification of omacetaxine, 40-DMHHT, and
cephalotaxine in plasma and urine were each 0.100 ng/mL.
The precision and accuracy of the method were acceptable,
with a coefficient of variation percentage (CV%) B4.5 % for
each analyte and bias values ranging from -5.2 to ?5.3 %.
For urinalysis, 400 lL samples of urine were processed
using solid-phase extraction. Chromatographic conditions
and equipment were identical to those involved in the plasma
method. The precision and accuracy of the method were
acceptable, with a CV% of B3.5 % for each analyte and bias
values ranging from -7.3 to ?4.0 %.
Noncompartmental pharmacokinetic analysis was con-
ducted using WinNonlin Professional software, version
5.2.1 (Pharsight Corp, Mountain View, CA). Cmax (days 1
and 11), Tmax (days 1 and 11), and the minimum-observed
plasma drug concentration during the steady-state dosing
interval on day 11 (Cmin) were estimated from the plasma
concentration versus time curve. The area under the plasma
concentration versus time curve (AUC) from time 0 to the
last sampling time point (AUClast; day 1 only) and AUC
from time 0 to the end of a 24-h interval (AUCs; day 11
only) were calculated using the linear trapezoidal rule.
Terminal-phase elimination rate constant values were
estimated by linear regression of the log concentration
versus time profile, and used to calculate the terminal-
phase half-life (t1/2). Derived pharmacokinetic parameters
included (1) mean steady-state concentration, calculated as
AUCs/s; (2) the AUC extrapolated to infinite time fol-
lowing the first dose (AUCinf); (3) the apparent clearance
(CL/F) following the first dose and the dose on day 11,
calculated as the dose divided by AUCinf (day 1) or AUCs
(day 11); (4) the apparent volume of distribution in the
terminal phase (Vz/F); and (5) the mean accumulation ratio
(Racc) between day 1 and day 11.
Safety and efficacy assessments
At baseline, all patients underwent a complete physical
examination and chest X-ray. Vital signs, ECOG perfor-
mance status, complete blood count with differential and
platelet count, and serum chemistries were evaluated at
baseline and weekly during the study. Urinalysis was per-
formed at baseline and on study days 11 and 29. A serial
12-lead electrocardiogram was conducted at baseline and
on study days 1 (predose and 0.5, 1, 2, 4, 8, and 12 h
postdose), 11 (following the 21st dose), 15, and 28. Cor-
rected QT intervals [using Bazett’s correction and Frider-
icia’s correction of QT interval formulae (QTcB and
QTcF)] were summarized with respect to change from
baseline by visit and time point. At each visit, patients were
monitored for AEs, and the duration, intensity, and causal
relationship with study drug were evaluated. The severity
of AEs was assessed using the National Cancer Institute’s
Common Terminology Criteria for Adverse Events, ver-
sion 3.0.
Baseline tumor evaluations were conducted within
28 days prior to first dose of study drug and repeated
during the last week of cycle 2; these evaluations included
bone marrow aspiration in patients with hematologic
malignancies and computed tomography or magnetic res-
onance imaging in patients with solid tumors. In patients
with solid tumors and measurable disease, response was
assessed using RECIST criteria [21]. In patients with
hematologic malignancies, response was assessed according
Cancer Chemother Pharmacol (2013) 71:35–41 37
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to commonly accepted criteria for CML as well as the




Twenty-one patients were enrolled at 3 United States sites
from May to October of 2008. All patients received at least
1 dose of study drug. Thirteen patients (62 %) completed
cycle 1 and went on to cycle 2; 10 of these patients (48 %)
completed all 28 doses within 14 days in the first cycle.
Two patients completed the second cycle of treatment, 1 of
whom was approved to continue treatment and received a
third cycle. Most common reasons for discontinuation were
disease progression (52 %) and withdrawal of consent
(24 %); no patients discontinued due to toxicity.
Patient characteristics are summarized in Table 1.
Notably, patients exhibited a wide range in body weight
(47.3–122.5 kg). Overall, a variety of tumor types were
represented: 17 patients had solid tumors, including colon
cancer (n = 6), pancreatic cancer (n = 3), lung cancer
(n = 2), prostate cancer (n = 2), and squamous cell carci-
noma, cervical cancer, hepatocellular carcinoma, and can-
cer of the parotid gland (n = 1 each). Hematologic cancers
included AML, multiple myeloma, Hodgkin lymphoma,
and diffuse large B-cell lymphoma in 1 patient each.
Pharmacokinetic profile
Pharmacokinetic data were available for all 21 patients on
day 1; 10 of 21 patients had complete data for estimating
pharmacokinetic parameters on day 11. The pharmacoki-
netic parameters of omacetaxine are summarized in
Table 2. Omacetaxine was rapidly absorbed into the blood
following SC injection, as measurable plasma omacetaxine
concentrations were observed at 0.5 h after the first dose in
all but 1 of 21 patients. Mean Tmax was 0.55 and 0.60 h on
days 1 and 11, respectively. Mean Cmax values were higher
on day 11 (36.2 ng/mL) than on day 1 (25.1 ng/mL).
AUCinf (day 1) and AUCs (day 11) values displayed a
pattern similar to Cmax.
Median omacetaxine plasma concentrations displayed a
biexponential decay when plotted on a semilogarithmic
scale (Fig. 1). The mean t1/2 after the first dose on day 1
(6.96 h) was nearly identical to that at steady state on day
11 (7.03 h). Mean apparent clearance (CL/F) on day 1 was
comparable to that on day 11. There was some degree of
omacetaxine accumulation during multiple twice-daily
dosing, as indicated by a mean Racc of 1.45. Measurable
plasma concentrations were sustained over the dosing
interval.
Notably, omacetaxine exposure was higher in males
versus female patients, as determined by AUCinf values
estimated on days 1 and 11. This finding may be partially
attributed to a lower body surface area observed in the
female cohort, and as a result, females may have received a
lower dose than males.
Plasma concentrations of 40-DMHHT were approxi-
mately 10 % of those for the parent compound; as observed
with omacetaxine, median plasma concentrations were
higher across the 12-hour sampling period on day 11 than
on day 1. Peak plasma 40-DMHHT concentrations were
attained at approximately 3 h (day 11) to 5 h (day 1) after
administration of omacetaxine. The elimination half-life of
40-DMHHT was more than twice that of omacetaxine
(approximately 16 h) and, in contrast to omacetaxine, the
decay pattern for 40-DMHHT was monoexponential
(Fig. 2). Plasma concentrations of cephalotaxine were just
above the lower limit of quantitation (0.100 ng/mL) in a
limited number of samples in only 2 patients; these data
were insufficient to permit calculation of pharmacokinetic
parameters for this metabolite.
Urinary excretion of omacetaxine was relatively low,
averaging 12 to 15 % of the administered dose on days 1
and 11, respectively. The amount of 40-DMHHT excreted
in the urine was 4 to 5 %, and the amount of cephalo-
taxine recovered in the urine was negligible at 0.07 to
0.14 %.
Safety
The most common AEs (all grades) reported were anemia
(71 %), thrombocytopenia (67 %), fatigue (62 %), and
diarrhea (57 %) (Table 3). Seventeen patients experienced
at least one grade 3/4 AE, most commonly thrombocyto-
penia (48 %), neutropenia (33 %), and anemia (19 %).
Table 1 Patient demographics and baseline characteristics
All patients (N = 21)
Median (range) age, years 58 (40–76)
Male/female, n (percentage) 13 (62)/8 (38)
Race, n (percentage)
Caucasian 21 (100)




Median (range) weight, kg 71.4 (47.3–122.5)
Median (range) BSA, m2 1.8 (1.4–2.4)
BSA body surface area; ECOG PS Eastern Cooperative Oncology
Group performance status
38 Cancer Chemother Pharmacol (2013) 71:35–41
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Two patients experienced serious AEs that were considered
by the investigator to be possibly or probably related to
study drug (1 episode of grade 3 febrile neutropenia and 1
episode of grade 2 hypotension).
During cycle 1, the highest mean change in QTcB
(6.2 ms) and QTcF (4.2 ms) occurred on day 1 at 8 h
postdose. Two patients demonstrated a grade 2 QTcB
[470 ms only on day 1 of treatment; 1 of these patients
also showed a grade 2 QTcF [470 ms. Notably, the latter
patient had a baseline QTcB of 463 ms. No apparent cor-
relation was observed between peak plasma concentration
(Cmax on day 1 was 11.7 and 38.7 ng/mL) or steady-state
concentration and absolute QTc value or change in QTc.
No clinical events were documented in relation to QTc
intervals [450 ms.
Response
Seven patients underwent tumor evaluation at the end of
cycle 2. No complete or partial responses were achieved.
Stable disease was observed in 3 patients (1 each with
prostate, cervical, and pancreatic cancer). Two additional
patients (1 with squamous cell carcinoma and 1 with
pancreatic cancer) underwent unscheduled tumor evalua-
tions 6 to 7 weeks after treatment initiation which were
consistent with radiographic evidence of stable disease.
Objective responses were not observed in patients with
hematologic malignancies.
Discussion
This study evaluated the pharmacokinetic and safety pro-
files of omacetaxine administered SC at a dose of 1.25
mg/m2 BID for 14 days every 28 days in patients with
advanced solid and hematologic tumors. Although formal
studies have not been conducted to determine the bio-
availability of omacetaxine, a cross-study comparison of
systemic exposure following IV and SC administration
indicates that bioavailability is approximately 70 to 90 %
[25]. In the current study, SC omacetaxine was rapidly
absorbed into plasma, as evidenced by mean tmax values of
0.55 and 0.60 h in single- and multiple-dose settings,
Table 2 Mean (CV%) pharmacokinetic parameters of omacetaxine
1.25 mg/m2 BID
PK parameter, unita Single dose
(day 1; n = 21)
Multiple dose
(day 11; n = 10)
Cmax, ng/mL 25.1 (56.0) 36.2 (55.6)
Tmax, h 0.55 (27.1) 0.60 (36.1)
Cmin, ng/mL N/A 8.12 (91.1)
Cavg, ng/mL N/A 15.7 (72.3)
kz, 1/h 0.111 (31.9) 0.109 (36.4)
t, h 6.96 (35.0) 7.03 (31.8)
AUCinf, h ng/mL 136.2 (70.3) N/A
AUClast, h ng/mL 91.7 (63.5) N/A
AUCs, h ng/mL N/A 188.0 (72.3)
Racc N/A 1.45 (16.2)
CL/F, L/h/m2 13.5 (64.0) N/A
CLss/F, L/h/m
2 N/A 10.5 (76.3)
Vz/F, L/m
2 126.8 (63.9) 66.2 (59.2)
a In general, there was moderate to high interpatient variability,
ranging from 30 to 75 % CV% in the key parameters, although the
Racc variability among the individual patients was lower, with a CV%
of 16.2 %
kz, terminal-phase elimination rate constant; AUCs, AUC during a
dosing interval, s, at steady state; AUC, area under the plasma drug
concentration versus time curve; AUCinf, AUC extrapolated to infinite
time following the first dose; AUClast, AUC to the last sampling time;
BID, twice daily; Cavg, average steady-state plasma drug concentra-
tion; CL/F, apparent clearance divided by bioavailability (CL/F)
values following the first dose and the dose on day 11; CLss/F,
apparent clearance divided by bioavailability (CL/F) values at steady
state; Cmax, maximum-observed plasma drug concentration; Cmin,
minimum-observed plasma drug concentration during the steady-state
dosing interval on day 11; CV%, coefficient of variation (percentage);
PK, pharmacokinetic; Racc, accumulation ratio between day 1 and day
11; t1/2, elimination half-life; Tmax, time of the Cmax; Vz/F, apparent
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Fig. 1 Median plasma omacetaxine concentration–time plots for




0 2 4 6 8 10 12
Time (h)















Fig. 2 Median plasma 40-DMHHT concentration–time plots for days
1 and 11. The y-axis scale is 1/10th that of Figure 1
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respectively. Mean peak and steady-state omacetaxine
concentrations at day 11 were approximately 1.5-fold
higher than single-dose levels. In vitro studies in leukemic
cells lines have shown the half-maximal inhibitory con-
centration (IC50) for omacetaxine to be 32 ng/mL or less
[26]; notably, the mean Cmax observed on day 11 was
36.2 ng/mL, indicating that the recommended dose and
schedule may produce plasma concentrations associated
with a pharmacodynamic effect. Drug exposure (AUC) was
lower in females as compared to males, but the relationship
to response is unclear. The relatively high apparent volume
of distribution after SC administration suggests that
omacetaxine is distributed beyond the vasculature into the
tissues. Omacetaxine has previously been demonstrated to
penetrate the blood–brain barrier [27].
The pharmacokinetic profile of the major metabolite of
omacetaxine, 40-DMHHT, was generally similar following
single and multiple doses. Peak plasma concentrations of
40-DMHHT, the primary metabolite of omacetaxine, were
observed at 3 to 5 h after drug administration; the decline
following maximal concentrations occurred more slowly
than for omacetaxine, with a mean t1/2 of approximately
16 h, indicating slow conversion of omacetaxine to 40-
DMHHT and/or slow elimination of 40-DMHHT. Steady-
state AUC values showed that exposure to 40-DMHHT
was approximately 13 % of that for omacetaxine. In vitro
evidence suggests that 40-DMHHT has little or no
pharmacodynamic activity [20]. Levels of cephalotaxine,
the other known metabolite of omacetaxine, were unde-
tectable in most patients.
Urinary excretion data indicate that less than 15 % of
the administered dose of omacetaxine is excreted as
unchanged drug, suggesting that dose adjustments may not
be required in patients with renal impairment.
The toxicity profile of SC omacetaxine observed in this
study was similar to that observed in other clinical studies
[6, 17–19]. Myelosuppression was the major AE, primarily
consisting of thrombocytopenia and neutropenia. Nonhe-
matologic AEs were mainly grades 1 and 2 in severity.
Omacetaxine produced no clinically apparent effects rela-
ted to QT interval prolongation. Plasma concentrations of
omacetaxine among patients with QTc intervals above
450 ms were within the range of those observed in patients
with QTc values less than 450 ms.
In conclusion, the safety and pharmacokinetic profile of
omacetaxine observed in this study, in particular the con-
centrations achieved and the t1/2, further support a twice-
daily dosing schedule for omacetaxine as an effective
alternative to continuous IV dosing.
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